biosimilar

Abbott receives regulatory approval for the first denosumab biosimilar in Thailand, expanding access to bone disease treatment

Abbott's denosumab biosimilar is the first approved in Thailand, making advanced therapy for osteoporosis and cancer-related bone loss more affordable for…

3 weeks ago

Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Basel, August 7, 2025 – Sandoz…

1 month ago

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA

AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has…

1 month ago

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first…

4 months ago